Primary Site >> Colorectal Cancer
Gene >> CTLA4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. PMID: 9366448 |
Ref: Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. PMID: 15289349 |
Ref: CTLA4 gene polymorphism in Italian patients with colorectal adenoma and cancer. PMID: 15888281 |
Ref: Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. PMID: 16489051 |
Ref: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. PMID: 17289891 Ref: High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. PMID: 17678726 Ref: Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. PMID: 17932815 Ref: Immunotherapy and immunoescape in colorectal cancer. PMID: 17990348 Ref: CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. PMID: 18031393 |
Ref: Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. PMID: 18774925 Ref: Cytotoxic-T-lymphocyte-associated antigen 4 blockade abrogates protection by regulatory T cells in a mouse model of microbially induced innate immune-driven colitis. PMID: 18824539 Ref: Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). PMID: 19343143 |
Ref: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. PMID: 19706802 |
Ref: CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. PMID: 19787358 Ref: Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. PMID: 20140740 Ref: Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. PMID: 20384858 Ref: Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. PMID: 20460483 Ref: Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. PMID: 20498386 Ref: Tremelimumab. PMID: 20698721 Ref: Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. PMID: 20924130 |
Ref: Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. PMID: 21376048 Ref: The immune response to tumors as a tool toward immunotherapy. PMID: 22190975 |
Ref: Accumulation of CCR4(+)CTLA-4 FOXP3(+)CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells. PMID: 22319577 Ref: Novel agents in early phase clinical studies on refractory pancreatic cancer. PMID: 22406592 Ref: [Therapeutic monoclonal antibodies in oncology]. PMID: 22863361 |
Ref: Tim-3 expression defines regulatory T cells in human tumors. PMID: 23526963 Ref: Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. PMID: 23873089 Ref: Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. PMID: 23986643 |
Ref: Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(-) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. PMID: 24064667 Ref: CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. PMID: 24316550 Ref: Colorectal cancer and immunity: what we know and perspectives. PMID: 24833840 Ref: Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. PMID: 24906621 Ref: Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. PMID: 25287912 Ref: Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. PMID: 25436113 |
Ref: The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. PMID: 25358689 Ref: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. PMID: 25363763 Ref: The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. PMID: 25583798 Ref: CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis. PMID: 25595911 Ref: The association of CTLA-4 A49G polymorphism with colorectal cancer risk in a Chinese Han population. PMID: 25689638 Ref: Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. PMID: 25730880 Ref: Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta analysis. PMID: 25785040 Ref: Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. PMID: 25823653 Ref: Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. PMID: 25943534 Ref: Immune signature of tumor infiltrating immune cells in renal cancer. PMID: 25949868 Ref: An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. PMID: 25949894 Ref: Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. PMID: 25993015 Ref: Association between cytotoxic T-lymphocyte antigen-4 +49A/G polymorphism and colorectal cancer risk: a meta-analysis. PMID: 26064271 Ref: Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? PMID: 26140250 Ref: Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. PMID: 26187615 Ref: Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. PMID: 26209749 Ref: Individual and Combined Effects of CTLA4-CD28 Variants and Oxidant-Antioxidant Status on the Development of Colorectal Cancer. PMID: 26408701 Ref: STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. PMID: 26607445 |
Ref: IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. PMID: 26910920 Ref: Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. PMID: 26959743 Ref: Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. PMID: 27039171 Ref: Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. PMID: 27099521 Ref: Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. PMID: 27230929 Ref: Immunotherapy of Colorectal Cancer. PMID: 27259331 Ref: The clinical impact of ICOS signal in colorectal cancer patients. PMID: 27467961 Ref: [Phenotypic characteristics of LAP(+) CD4(+) T lymphocytes in colorectal cancer tissues]. PMID: 27531479 Ref: The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. PMID: 27553906 Ref: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PMID: 27610613 |
Ref: Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. PMID: 27893434 Ref: Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer. PMID: 28084319 Ref: Role of LAP(+)CD4(+) T cells in the tumor microenvironment of colorectal cancer. PMID: 28210081 Ref: Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. PMID: 28287848 Ref: Intratumoral FoxP3(+)Helios(+) Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. PMID: 28603527 Ref: Immune Checkpoints as a Target for Colorectal Cancer Treatment. PMID: 28635639 Ref: Targeting latency-associated peptide promotes antitumor immunity. PMID: 28763794 Ref: The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. PMID: 28807001 Ref: Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies. PMID: 28847682 Ref: The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. PMID: 29113654 |
Ref: Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. PMID: 29120224 Ref: Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. PMID: 29122838 Ref: Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. PMID: 29223828 Ref: Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. PMID: 29437869 Ref: CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. PMID: 29520442 Ref: Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. PMID: 29542354 Ref: Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. PMID: 29664018 Ref: Immunotherapy of Colon Cancer. PMID: 29705788 Ref: Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. PMID: 29710228 Ref: Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer. PMID: 29770915 Ref: Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/betacatenin signaling activation (Review). PMID: 29786110 Ref: Diagnostic value of peripheral blood immune profiling in colorectal cancer. PMID: 29854709 Ref: RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. PMID: 29872559 Ref: ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy. PMID: 29879883 Ref: Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. PMID: 29900067 Ref: Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. PMID: 29915296 Ref: Association of cytotoxic T-lymphocyte antigen 4 rs231775 gene polymorphism with colorectal cancer risk. PMID: 29970719 Ref: RORgammat-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells. PMID: 29991500 Ref: DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. PMID: 30081950 Ref: CTLA4 tagging polymorphisms and risk of colorectal cancer: a case-control study involving 2,306 subjects. PMID: 30122952 Ref: Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. PMID: 30271205 Ref: A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management. PMID: 30309639 Ref: Association of IL-36gamma with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. PMID: 30315348 |